[go: up one dir, main page]

MX2008001711A - Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa. - Google Patents

Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa.

Info

Publication number
MX2008001711A
MX2008001711A MX2008001711A MX2008001711A MX2008001711A MX 2008001711 A MX2008001711 A MX 2008001711A MX 2008001711 A MX2008001711 A MX 2008001711A MX 2008001711 A MX2008001711 A MX 2008001711A MX 2008001711 A MX2008001711 A MX 2008001711A
Authority
MX
Mexico
Prior art keywords
levodopa
extended release
tablet
carbidopa
release form
Prior art date
Application number
MX2008001711A
Other languages
English (en)
Inventor
Joaquina Faour
Glenn A Meyer
Ethel C Feleder
Marcelo A Ricci
Juan A Vergez
Marcelo Befumo
Original Assignee
Osmotica Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osmotica Corp filed Critical Osmotica Corp
Publication of MX2008001711A publication Critical patent/MX2008001711A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invencion proporciona un comprimido que proporciona un comprimido de liberacion extendida que contiene una forma de liberacion extendida de carbidopa y una forma de liberacion extendida de levodopa. El comprimido opcionalmente ademas comprende una composicion de liberacion inmediata o rapida de carbidopa y/o levodopa. La composicion de liberacion extendida en el comprimido excluye un polimero de control de la velocidad de liberacion, y un recubrimiento de control de la velocidad de liberacion; sin embargo, la liberacion de la carbidopa y/o levodopa es independientemente de forma opcional retrasada por un periodo de retraso. La invencion tambien proporciona un comprimido que posee una forma de liberacion extendida de levodopa y una forma de liberacion rapida o inmediata de carbidopa. Un comprimido puede contener levodopa presente en una forma de liberacion extendida y una forma de liberacion rapida o inmediata, y carbidopa presente en una forma de liberacion extendida y en forma de liberacion rapida o inmediata. El comprimido es usado para tratar la enfermedad de Parkinson y otros desordenes, enfermedades o sindromes relacionados con el movimiento. La figura mas representativa de la invencion es la numero 1.
MX2008001711A 2005-08-05 2006-08-04 Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa. MX2008001711A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70583905P 2005-08-05 2005-08-05
PCT/CR2006/000006 WO2008000194A1 (en) 2005-08-05 2006-08-04 Extended release solid pharmaceutical composition containing carbidopa and levodopa

Publications (1)

Publication Number Publication Date
MX2008001711A true MX2008001711A (es) 2008-04-07

Family

ID=38458530

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008001711A MX2008001711A (es) 2005-08-05 2006-08-04 Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa.

Country Status (11)

Country Link
US (1) US20070275060A1 (es)
EP (1) EP1909768A1 (es)
JP (1) JP2009502987A (es)
KR (1) KR20080033354A (es)
CN (1) CN101516351A (es)
AR (1) AR055106A1 (es)
AU (1) AU2006345054A1 (es)
BR (1) BRPI0614091A2 (es)
CA (1) CA2614389A1 (es)
MX (1) MX2008001711A (es)
WO (1) WO2008000194A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100316712A1 (en) * 2006-12-22 2010-12-16 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
US8741918B2 (en) * 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
WO2009076983A2 (en) * 2007-12-17 2009-06-25 Pharmathen S.A. Improved pharmaceutical composition containing non-ergoline dopamine agonist and method for the preparation thereof
EP2234963B1 (en) 2007-12-28 2020-04-08 Impax Laboratories, LLC Controlled release formulations of levodopa and uses thereof
DE102008022520A1 (de) * 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
ES2476765T3 (es) * 2008-08-22 2014-07-15 Wockhardt Limited Composición farmacéutica de liberación sostenida de entacapona o sales de la misma
US8840934B2 (en) * 2009-01-02 2014-09-23 Rainbow Pharmaceutical Sa Uses of ammonium chloride
WO2010121159A1 (en) * 2009-04-17 2010-10-21 Somalabs, Inc. Method for the induction of a reward response by modulation of dopaminergic systems in the central nervous system
US9779214B2 (en) 2012-01-06 2017-10-03 Molecular Health Gmbh Systems and methods for personalized de-risking based on patient genome data
WO2014006571A2 (en) * 2012-07-02 2014-01-09 Ranbaxy Laboratories Limited Extended-release pharmaceutical dosage forms of carbidopa and levodopa and processes of preparation thereof
CN102755310B (zh) * 2012-07-26 2016-06-15 温天文 一种含有左旋多巴的组合物药物制剂
WO2014074797A1 (en) 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
US8545878B1 (en) * 2012-11-09 2013-10-01 Civitas Therapeutics, Inc. Capsules containing high doses of levodopa for pulmonary use
CN102924652B (zh) * 2012-11-26 2014-07-23 无锡朗立药业有限公司 聚丙烯酸树脂ⅳ的精制方法
US10994013B2 (en) 2013-04-24 2021-05-04 Temple University—Of the Commonwealth System of Higher Education Solid dosage form containing arabinogalactan
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
EP3782614A1 (en) 2013-10-07 2021-02-24 Impax Laboratories, LLC Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US9808478B2 (en) * 2015-04-17 2017-11-07 Steven Loyd Control release of fat soluble antioxidants from an oral formulation and method
WO2018034626A1 (en) 2016-08-18 2018-02-22 İlko İlaç Sanayi Ve Ticaret Anonim Şirketi Antiparkinson tablet formulation with improved dissolution profile
JP7066351B2 (ja) * 2017-08-18 2022-05-13 大原薬品工業株式会社 良好な徐放性を有する、レボドパ含有小型化錠剤
EP3773532A4 (en) * 2018-03-29 2022-11-02 Avion Pharmaceuticals, LLC FRACTIONAL LEVODOPA DOSAGE AND USE
CN112638367A (zh) * 2019-09-06 2021-04-09 南京三迭纪医药科技有限公司 制成-可实现目标pk曲线的口服药物剂型及其设计和制备方法
EP4255495A4 (en) 2020-12-03 2025-10-08 Battelle Memorial Institute COMPOSITIONS OF POLYMERIC NANOPARTICLES AND DNA NANOSTRUCTURES AND METHODS FOR NON-VIRAL DELIVERY
CA3196650A1 (en) 2020-12-22 2022-06-30 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
CN113616621B (zh) * 2021-08-19 2025-03-14 北京世桥生物制药有限公司 一种左旋多巴和卡比多巴控释制剂及其制备方法
CN116098883A (zh) * 2021-12-26 2023-05-12 长沙晶易医药科技股份有限公司 一种卡左双多巴胃滞留缓释片及其制备方法和用途
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems
WO2025172348A1 (en) * 2024-02-12 2025-08-21 Contera Pharma A/S Delayed dual-pulse oral formulation

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361545A (en) * 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
DE3437694A1 (de) * 1984-10-15 1986-04-17 Boehringer Ingelheim Vetmedica GmbH, 6507 Ingelheim Verwendung einer substanz als sedativum
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
ZA889189B (en) * 1986-06-16 1989-08-30 Merck & Co Inc Controlled release combination of carbidopa/levodopa
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
US5192550A (en) * 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5624960A (en) * 1991-01-23 1997-04-29 Isis Pharma Gmbh Orally administrable drugs for the treatment of central dopamine deficiency conditions
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5266332A (en) * 1991-12-06 1993-11-30 Alza Corporation Method for administering anti-Parkinson drug
US5840756A (en) * 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
US6361796B1 (en) * 1996-10-25 2002-03-26 Shire Laboratories, Inc. Soluble form osmotic dose delivery system
US6756056B2 (en) * 1997-04-08 2004-06-29 Alan A. Rubin Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
IL159813A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US20030224045A1 (en) * 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
US7094427B2 (en) * 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
EP1863455A1 (en) * 2005-03-28 2007-12-12 Orexo AB New pharmaceutical compositions useful in the treatment of parkinson's disease
US20070003621A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Dosage forms for movement disorder treatment

Also Published As

Publication number Publication date
AR055106A1 (es) 2007-08-08
JP2009502987A (ja) 2009-01-29
WO2008000194A1 (en) 2008-01-03
BRPI0614091A2 (pt) 2011-03-09
CN101516351A (zh) 2009-08-26
US20070275060A1 (en) 2007-11-29
AU2006345054A1 (en) 2008-01-03
KR20080033354A (ko) 2008-04-16
EP1909768A1 (en) 2008-04-16
CA2614389A1 (en) 2008-01-03

Similar Documents

Publication Publication Date Title
MX2008001711A (es) Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa.
TW200633730A (en) Oral disintegrating dosage forms
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
AU2007221366A8 (en) Oxyntomodulin derivatives
SG166093A1 (en) Inhibitors of brutonæs tyrosine kinase
NZ591326A (en) An extended release pharmaceutical composition of entacapone or salts thereof
EP3311818A3 (en) Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
MX2009003305A (es) Inhibidores de co-transportador de glucosa de sodio 2 y metodo para su uso.
MY148496A (en) Dpp iv inhibitor formulations
MY161991A (en) Proteasome inhibitors
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
CL2008000738A1 (es) Compuestos derivados de malonamida; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la depresion, enfermedad de parkinson y alzheimer, entre otras enfermeda
WO2008053297A3 (en) Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa
WO2007061939A3 (en) Metabolite derivatives of the hdac inhibitor fk228
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
MY149306A (en) Solid preparation containing an insulin sensitizer
GB2431346C (en) A combination composition comprising paracetamol and ibuprofen
IL185723A0 (en) Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
UA102111C2 (uk) Фармацевтична композиція у вигляді разової пероральної дози, що містить леводопу, карбідопу і ентакапон або їх солі
WO2005112635A3 (en) Uridine effects on dopamine release
MX2009008108A (es) Composicion farmaceutica que contiene una combinacion de tramadol y ketoprofeno.
MXPA05003718A (es) Compuestos x-nitro, sus composiciones farmaceuticas y sus usos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal